| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA749: Liraglutide for managing obesity in people aged 12 to 17 (terminated) |
|
Medicine details |
|
| Medicine name | liraglutide (Saxenda®) |
| Formulation | 6 mg/ml solution for injection |
| Reference number | 3991 |
| Indication | As an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 to 17 years with: obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points)* and body weight above 60 kg. Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose *IOTF BMI cut-off points for obesity by sex between 12–18 years |
| Company | Novo Nordisk Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/09/2021 |
| NICE guidance | TA749: Liraglutide for managing obesity in people aged 12 to 17 (terminated) |